Bluebird Bio, a US-based gene therapy specialist, plans to float on the Nasdaq stock exchange with a market capitalization of about $328m.

Bluebird plans to offer 5 million shares at between $14 and $16 each, with a further $750,000 shares available if demand is strong.

Investment banks JP Morgan and BoA Merrill Lynch are Bluebird’s lead underwriters for the initial public offering (IPO), with legal counsel from Goodwin Procter and Ropes & Gray.

Bluebird Bio  posted a $6.5m net loss on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?